StockData

Intellia Therapeutics vs Trinity Biotech

NTLA and TRIB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NTLA and TRIB compare

Intellia Therapeutics grew revenue faster over the last twelve months (12.6% versus −28.9% for Trinity Biotech).

Trinity Biotech keeps more of each dollar of sales as profit, with a net margin of −85.4% compared with −672% at Intellia Therapeutics.

Intellia Therapeutics scores higher on the StockData Score (8 against 1 for Trinity Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNTLATRIB
Size and price
Market cap$1.4B–
Share price$9.86$5.38
Change, 1 year13.7%−79.0%
Change, 5 years−91.3%−98.0%
Beta (5Y)1.643.56
Employees377287
StockData Score
Total score8 (better)1
Valuation score1 (better)0
Growth score11
Performance score1 (better)0
Health score5 (better)0
Dividend score00
Valuation
P/S23.2×–
P/B1.9×–
FCF yield−25.2%–
Fair value$9.05–
Margin of safety−8.9%–
Growth
Revenue growth (TTM)12.6% (better)−28.9%
Revenue growth, 5Y average3.1% (better)−15.6%
Profitability
Gross margin–38.6%
Operating margin−712%−36.1% (better)
Net margin−672%−85.4% (better)
FCF margin−586%−13.7% (better)
Return on equity−6425%–
Financial health
Debt / equity0.00–
Interest coverage–−0.7×
Current ratio6.65 (better)0.25
Altman Z-score0.91–
Piotroski F-score34 (better)
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions103%0.01%
Held by insiders2.0%51.7%
Insider net buying, 12 months−$869K–
Short interest, % of float32.3%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.